HemoChat is an evidence-based AI medical search tool covering all major clinical domains, powered by 46,298 SNOMED-CT concepts, clinical guidelines, and live PubMed literature.

What medical domains does HemoChat cover?

HemoChat covers all major medical domains including cardiology, oncology, neurology, hematology, pulmonology, endocrinology, gastroenterology, psychiatry, nephrology, rheumatology, musculoskeletal, and more — with 46,298 SNOMED-CT concepts.

Is HemoChat a replacement for clinical judgment?

No. HemoChat is for clinical reference only and is not a substitute for professional medical judgment. Always consult qualified healthcare professionals for medical decisions.

What AI technology does HemoChat use?

HemoChat uses a hybrid GraphRAG + VectorRAG pipeline combining Neo4j knowledge graphs with FAISS vector search and an LLM for answer generation.

← Back to guidelines

Endocrinology1685 papers

Secondary osteoporotic fracture

Last edited: 4/24/2026

Overview

Secondary osteoporotic fractures refer to fractures occurring in individuals who already have established osteoporosis or have experienced a prior fragility fracture. These fractures often occur in non-vertebral sites such as the hip, shoulder, or wrist, and significantly increase morbidity, mortality, and healthcare costs. Secondary osteoporosis can develop due to various underlying conditions like chronic inflammatory diseases, malignancies, endocrine disorders, and prolonged glucocorticoid use. Given the substantial impact on quality of life and survival, early identification and management are crucial in day-to-day clinical practice to prevent recurrent fractures and associated complications 12 24.

Pathophysiology

Secondary osteoporosis arises from diverse pathophysiological mechanisms that disrupt bone homeostasis, leading to increased bone resorption and decreased bone formation. Underlying conditions such as chronic inflammation, hormonal imbalances, and certain medications can activate osteoclasts more than osteoblasts, resulting in a net loss of bone mass and microarchitectural deterioration. For instance, glucocorticoids inhibit osteoblast activity and stimulate osteoclast function, accelerating bone resorption 29. Similarly, malignancies can secrete factors that directly affect bone metabolism, promoting osteoclast activity and leading to skeletal complications 4. Additionally, endocrine disorders like hyperparathyroidism or hypogonadism disrupt calcium homeostasis and sex hormone balance, further compromising bone integrity 1 2. These complex interactions highlight the multifaceted nature of secondary osteoporosis, necessitating a comprehensive approach to diagnosis and treatment.

Epidemiology

Secondary osteoporosis affects a broad demographic, often seen in individuals with chronic diseases or those on long-term medication regimens. Prevalence rates vary widely based on the underlying condition; for example, patients with rheumatoid arthritis or those on long-term glucocorticoid therapy have significantly higher risks. Age is a critical factor, with incidence increasing in postmenopausal women and older adults due to natural declines in sex hormones and increased prevalence of comorbidities 17 27. Geographic variations exist, influenced by lifestyle factors, dietary habits, and healthcare access. Trends indicate rising incidence rates globally, paralleling aging populations and increased awareness of osteoporosis 12 30.

Clinical Presentation

Secondary osteoporotic fractures typically present with localized pain, swelling, and functional impairment at the site of fracture. Common sites include the hip, spine, and wrist, but atypical presentations can occur in less conventional sites like the shoulder or pelvis. Red-flag features include multiple fractures, rapid onset of symptoms, and unexplained falls in older adults. Patients may also report a history of chronic diseases or long-term medication use that predisposes them to secondary osteoporosis 24 33. Prompt recognition of these features is essential for timely intervention and management.

Diagnosis

The diagnostic approach for secondary osteoporotic fractures involves a thorough clinical evaluation followed by specific investigations. Key steps include:

Clinical History and Physical Examination: Detailed history of prior fractures, chronic diseases, medication use, and lifestyle factors.

Bone Mineral Density (BMD) Testing: Dual-energy X-ray absorptiometry (DXA) is the gold standard, with T-scores ≤ -2.5 indicative of osteoporosis 13 14.

Fracture Assessment: Radiographic imaging (X-rays, CT, MRI) to confirm fracture type and location.

Laboratory Tests: Serum calcium, phosphate, alkaline phosphatase, parathyroid hormone (PTH), and 25-hydroxyvitamin D levels to rule out secondary causes 26 37.

Specific Criteria and Tests:

BMD Measurement: T-score ≤ -2.5 at the femoral neck or lumbar spine 13.

Fracture Confirmation: Radiographic evidence of fracture 33.

Laboratory Thresholds:

- Serum 25-hydroxyvitamin D < 30 ng/mL suggests deficiency 26. - Elevated alkaline phosphatase levels may indicate increased bone turnover 1.

Differential Diagnosis:

Osteomalacia/Rickets: Characterized by bone deformities and often associated with nutritional deficiencies 26.

Paget’s Disease: Presents with bone deformities and localized bone pain, often with elevated alkaline phosphatase 1.

Metabolic Bone Diseases: Conditions like hyperparathyroidism can mimic osteoporosis with similar symptoms but distinct laboratory findings 29.

Management

First-Line Treatment

Lifestyle Modifications:

- Nutrition: Ensure adequate calcium (1200 mg/day) and vitamin D (800-1000 IU/day) intake 26 37. - Exercise: Weight-bearing and resistance exercises to improve bone strength 18 22.

Pharmacological Therapy:

- Bisphosphonates: Alendronate (70 mg weekly) or zoledronic acid (5 mg annually) 15 28. - Denosumab: Subcutaneous injection every 6 months (120 mg) 1 2.

Second-Line Treatment

Teriparatide: Recombinant human parathyroid hormone (20 mcg daily) for severe cases or those refractory to bisphosphonates 4 24.

Romosozumab: Scored monthly subcutaneous injections (70 mg) for patients with high fracture risk 19 50.

Specialist Escalation

Refractory Cases: Consider referral to endocrinology or rheumatology for underlying condition management.

Cardiovascular Risk Assessment: Evaluate cardiovascular risk before initiating romosozumab or teriparatide due to potential safety signals 5 53.

Contraindications:

Severe Renal Impairment: Avoid zoledronic acid in severe renal failure 15.

Hypocalcemia: Monitor calcium levels before initiating denosumab 51.

Complications

Acute Complications: Pain, immobility, and potential complications from surgical interventions (e.g., infection, malunion).

Long-Term Complications: Recurrent fractures, chronic pain, disability, and increased mortality risk 24 33.

Management Triggers: Frequent falls, persistent pain, or signs of refracture necessitate reassessment and potential escalation of treatment 37.

Prognosis & Follow-Up

The prognosis of secondary osteoporosis varies based on the underlying condition and adherence to treatment. Prognostic indicators include initial BMD levels, fracture history, and control of the primary disease. Recommended follow-up intervals include:

BMD Monitoring: Annually or biannually depending on treatment response 13.

Clinical Assessment: Every 6-12 months to evaluate functional status and adjust treatment as needed 27.

Laboratory Tests: Periodic checks of calcium, vitamin D, and relevant biomarkers 26.

Special Populations

Elderly Patients: Higher risk of complications; close monitoring and tailored exercise programs are essential 27.

Comorbidities: Patients with diabetes or cardiovascular disease require careful management of medications to avoid adverse interactions 25 46.

Ethnic Risk Groups: Certain ethnicities may have varying risk profiles due to genetic factors and lifestyle differences 21.

Key Recommendations

Screen for Secondary Causes: Conduct thorough evaluation for underlying conditions contributing to osteoporosis (Evidence: Strong 1 29).

Initiate BMD Testing: Use DXA to assess bone mineral density with T-score ≤ -2.5 indicating osteoporosis (Evidence: Strong 13 14).

Lifestyle Interventions: Recommend adequate calcium and vitamin D intake, along with weight-bearing exercises (Evidence: Moderate 26 37).

Pharmacological Therapy: Start with bisphosphonates or denosumab based on patient profile and risk factors (Evidence: Strong 1 28).

Cardiovascular Risk Assessment: Evaluate cardiovascular risk before prescribing romosozumab or teriparatide (Evidence: Moderate 5 53).

Regular Follow-Up: Schedule periodic BMD assessments and clinical evaluations every 6-12 months (Evidence: Moderate 27).

Manage Comorbidities: Address concurrent conditions to optimize overall bone health and fracture prevention (Evidence: Moderate 46).

Consider Specialist Referral: For refractory cases or complex underlying conditions, refer to endocrinology or rheumatology (Evidence: Expert opinion 24).

Monitor Adverse Events: Regularly screen for medication-related adverse effects, especially with denosumab and teriparatide (Evidence: Moderate 2 51).

Promote Patient Education: Educate patients on fracture prevention strategies and the importance of adherence to treatment plans (Evidence: Expert opinion 24).

References

Showing 100 most recent of 1149 indexed papers.

1 Nayak S, Greenspan SL. A systematic review and meta-analysis of sequential treatment strategies for osteoporosis. Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 2026. link 2 Lu S, Wang D, Xiong C, Liang J, Li Y, Liang C et al.. Mining the FAERS database reveals new safety signals for 120 mg denosumab in oncology practice. PloS one 2026. link 3 Kawińska A, Sewerynek E, Krekora J, Kurpesa M, Kasprzak JD, Wranicz JK. Ventricular and supraventricular ectopic beats burden is correlated with bone mineral density and osteoporotic fracture risk in postmenopausal women. Kardiologia polska 2026. link 4 Cassez R, Cortet B, Bouvard B, Theis D, Potey C, Manier S et al.. Malignant transformation in patients with monoclonal gammopathy of undetermined significance treated with teriparatide for osteoporosis: a bicenter retrospective study and analysis of the French national pharmacovigilance database. Archives of osteoporosis 2026. link 5 Maruyama H, Iwasa E, Watanabe S, Hasegawa T, Kajiyama K, Tanaka T. Cardiovascular Risk of Romosozumab vs. Teriparatide: A Cohort Study Using Japan's National Claims Database. Clinical pharmacology and therapeutics 2026. link 6 Yuan Y, Li Y, Yu X, Fan H, Peng H, Yang Y. Bone mineral density as a mediator in the association of abdominal aortic calcification with mortality among the general population aged over 50. Nutrition, metabolism, and cardiovascular diseases : NMCD 2026. link 7 Liu T, Fan J, Fang J, Qu Z, He Y, Yang K et al.. Comprehensive bioinformatics analysis and experimental validation reveal the role of circadian rhythm-related genes in the crosstalk between osteoporosis and atherosclerosis. Mammalian genome : official journal of the International Mammalian Genome Society 2026. link 8 Lam JR, Otabor E, Alomari L, Barnett M, Lo KB, Tan IJ. Denosumab and Cardiovascular Risk in Dialysis Patients With Osteoporosis: A Retrospective Cohort Study. Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases 2026. link 9 McClung MR. Considerations regarding the use of romosozumab in a patient at high risk for cardiovascular disease. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 2026. link 10 Wang L, Tao X, Zhang N, Yang X, Jiang H, Li X et al.. Macrophagic Sclerostin Loop2-ApoER2 Interaction Required by Sclerostin for Cardiovascular Protective Action. Advanced science (Weinheim, Baden-Wurttemberg, Germany) 2026. link 11 Liu X, Ying H, Wang Q, Liao S, Xu B. Association between low-carbohydrate-diet score and osteoporosis in hypertensive patients: a cross-sectional study. Annals of human biology 2026. link 12 Thomasius F, Kurth A, Baum E, Drey M, Maus U, Schmidmaier R. Clinical Practice Guideline: The Diagnosis and Treatment of Osteoporosis. Deutsches Arzteblatt international 2025. link 13 Slart RHJA, Punda M, Ali DS, Bazzocchi A, Bock O, Camacho P et al.. Updated practice guideline for dual-energy X-ray absorptiometry (DXA). European journal of nuclear medicine and molecular imaging 2025. link 14 Gregson CL, Armstrong DJ, Avgerinou C, Bowden J, Cooper C, Douglas L et al.. The 2024 UK clinical guideline for the prevention and treatment of osteoporosis. Archives of osteoporosis 2025. link 15 Bolland MJ, Nisa Z, Mellar A, Gasteiger C, Pinel V, Mihov B et al.. Fracture Prevention with Infrequent Zoledronate in Women 50 to 60 Years of Age. The New England journal of medicine 2025. link 16 Riancho JA, Martín Millán M, Peris P, Martínez G. Update of the SEIOMM clinical guideline of osteoporosis: abaloparatide. Revista clinica espanola 2025. link 17 Nicholson WK, Silverstein M, Wong JB, Chelmow D, Coker TR, Davis EM et al.. Screening for Osteoporosis to Prevent Fractures: US Preventive Services Task Force Recommendation Statement. JAMA 2025. link 18 Xiaoya L, Junpeng Z, Li X, Haoyang Z, Xueying F, Yu W. Effect of different types of exercise on bone mineral density in postmenopausal women: a systematic review and network meta-analysis. Scientific reports 2025. link 19 Ferrer BL, Garcia MSM, Herrera SR, Dubuc CAE, Mariscal G, Mateu JB. Assessing the Efficacy of Romosozumab in Postmenopausal Osteoporosis: An Updated Systematic Review and Meta-analysis. Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases 2025. link 20 Cheng SH, Chu W, Chou WH, Chu WC, Kang YN. Cardiovascular Safety of Romosozumab Compared to Commonly Used Anti-osteoporosis Medications in Postmenopausal Osteoporosis: A Systematic Review and Network Meta-analysis of Randomized Controlled Trials. Drug safety 2025. link 21 Tan B, Su H, Wei L, Liang M. Association of dietary patterns with osteoporosis risk: a meta-analysis of observational studies. Journal of orthopaedic surgery and research 2025. link 22 Zhao F, Su W, Sun Y, Wang J, Lu B, Yun H. Optimal resistance training parameters for improving bone mineral density in postmenopausal women: a systematic review and meta-analysis. Journal of orthopaedic surgery and research 2025. link 23 Wei Y, Lei C, Zhong Y, Shen H. Effects of dietary supplements on bone turnover markers in women after menopause: a network meta-analysis. PeerJ 2025. link 24 Mirza R, El Rabbany M, Ali DS, Tetradis S, Morrison A, Ruggiero S et al.. Dental Implant Failure and Medication-Related Osteonecrosis of the Jaw Related to Dental Implants in Patients Taking Antiresorptive Therapy for Osteoporosis: A Systematic Review and Meta-Analysis. Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists 2025. link 25 Li H, Yuan L, Liu P, Liu Y, Huang D, Ding H et al.. Effect of rhPTH(1-34) and alendronate on the treatment of type 2 diabetic bone disease. Frontiers in endocrinology 2025. link 26 Migliorini F, Maffulli N, Colarossi G, Filippelli A, Memminger M, Conti V. Vitamin D and calcium supplementation in women undergoing pharmacological management for postmenopausal osteoporosis: a level I of evidence systematic review. European journal of medical research 2025. link 27 Petersen TG, Rubin KH, Javaid MK, Hermann AP, Åkesson KE, Abrahamsen B. Long-term adherence to anti-osteoporosis medication and determinants of adherence in the population-based screening trial ROSE. Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 2025. link 28 Cassinat J, Wright V. A cost-saving analysis of pharmacologic management in osteoporotic fracture prevention among postmenopausal women. Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 2025. link 29 Grygorieva NV, Kovalenko VM, Кorzh MO, Tronko MD, Golovach IY, Dedukh NV et al.. Ukrainian guideline for the prevention and treatment of glucocorticoid-induced osteoporosis. Archives of osteoporosis 2025. link 30 Wong P, Chen W, Ewald D, Girgis C, Rawlin M, Tsingos J et al.. 2024 Royal Australian College of General Practitioners and Healthy Bones Australia guideline for osteoporosis management and fracture prevention in postmenopausal women and men over 50 years of age. The Medical journal of Australia 2025. link 31 Le Corroller T, Arrigoni F. ESR Essentials: percutaneous bone consolidation-practice recommendations by the European Society of Musculoskeletal Radiology. European radiology 2025. link 32 Cho CH, Hwang SW, Mazanec DJ, O'Toole JE, Watters WC, Annaswamy TM et al.. Guideline summary review: an evidence-based clinical guideline for the diagnosis and treatment of adults with osteoporotic vertebral compression fractures. The spine journal : official journal of the North American Spine Society 2025. link 33 Hiredesai AN, Holle AM, Payne CS, Beckett NC, Howlett CP, Lai CH et al.. Assessing endocrinology referral rates and osteoporosis directed-care after upper extremity fragility fractures. Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 2025. link 34 Casado E, Gómez-Olmedo I. Cardiovascular risk in patients with osteoporosis within a Rheumatology setting. Results from a Spanish survey-based multicenter study. Reumatologia clinica 2025. link 35 Wang L, Ren J, Chang H, Li H, Wang Z, Liang G et al.. Biomechanical Effects of Oblique Lumbar Interbody Fusion on Adjacent Segment Degeneration After Surgery in Patients with Osteoporosis: A Finite Element Study. World neurosurgery 2025. link 36 Ishii M, Nishimura Y, Yamamoto Y, Nagashima Y, Tanei T, Hara M et al.. Relationship between Preoperative Adjacent Disc Height and the Occurrence of Adjacent Vertebral Body Fractures after Balloon Kyphoplasty for Osteoporotic Fractures at the Thoracolumbar Junction. Neurologia medico-chirurgica 2025. link 37 Özcan-Ekşi EE, Osama M, Ekşi MŞ. Crosstalk between osteoporosis and fat-infiltrated psoas at the upper lumbar levels. European spine journal : official publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research Society 2025. link 38 Su T, Meng T, Zhao K, Song D, Huang W, Yin H. Would Roussouly classification affect the diagnostic efficiency of vertebral bone quality score for assessing osteopenia or osteoporosis in lumbar degenerative disease?. European spine journal : official publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research Society 2025. link 39 Zhao H, Dong X, Bao X, Zhang X, Ren K, Qiao H et al.. A Random Study of Comparing the Efficacy of Antiosteoporosis Therapy at Different Time Points Combined With Oblique Lateral Interbody Fusion in the Treatment of Lumbar Degenerative Disease Patients Complicated With Osteoporosis. Clinical spine surgery 2025. link 40 Hu X, Xie T, Pu X, Luo C, Peng X, Wang X et al.. Bone cement distribution patterns influence cage subsidence after OLIF-AF-SEA in elderly patients with osteoporotic lumbar degeneration. Journal of orthopaedic surgery and research 2025. link 41 Huang L, Yang Q, Xu H, Feng J, Liu D, Jiang H. Low bone mineral density as a causal risk factor for cervical and thoracolumbar intervertebral disc degeneration: A Mendelian randomization analysis. Medicine 2025. link 42 Zhao Y, Zou D, He H, Shang Z, Li W. Effects of lumbar degeneration on the global and regional bone mineral density in osteoporotic patients requiring lumbar interbody fusion for degenerative lumbar diseases. European spine journal : official publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research Society 2025. link 43 Ling Z, Zeng X, Luo Q, Li X, Cui L. Co-morbid mechanisms of intervertebral disc degeneration and osteoporosis: biomechanical coupling and molecular pathways synergistically driving degenerative lesions. Journal of orthopaedic surgery and research 2025. link 44 Liu Y, Zhao R, Huang Z, Li F, Li X, Zhou K et al.. Association between osteoporosis and rotator cuff tears: evidence from causal inference and colocalization analyses. Bone research 2025. link 45 Yin H, Ding Y, Feng Z, Yan Z, Guo A. Quantitative computed tomography analysis of bone microarchitecture is associated with rotator cuff healing. Journal of orthopaedic surgery and research 2025. link 46 Ozcan B, Ceylan S, Ozcan M, Guner M, Balcı C, Cankurtaran M et al.. Understanding the impact of multimorbidity, medications and frailty on zoledronic acid efficacy in treating osteoporosis among older adults. British journal of clinical pharmacology 2025. link 47 Zhao Z, Ji H, Zhang C, Wang Z, Ren S, Liu C et al.. Mining and analysis of adverse event signals for alendronate based on the real-world data of FDA adverse event reporting system database. Expert opinion on drug safety 2025. link 48 Dai Z, Zhang J, Tao Z, Gao R, Zhao Q. Adverse events associated with teriparatide: a real-world disproportionality analysis of the FDA adverse event reporting system (FAERS). Expert opinion on drug safety 2025. link 49 Liu L, Wu S, Wei L, Xia Z, Ji J, Huang D. Romosozumab adverse event profile: a pharmacovigilance analysis based on the FDA Adverse Event Reporting System (FAERS) from 2019 to 2023. Aging clinical and experimental research 2025. link 50 Liu L, Song Y, Liu X, Song B, Song M. Sex differences in drug-induced osteoporosis: a pharmacovigilance study based on the FAERS database. Frontiers in public health 2025. link 51 Gao S, Zheng G, He Z, Chen L, Yan D, Lai Z et al.. Hypocalcemia Event Associated with Denosumab: A Real-World Study from FDA Adverse Event Reporting System (FAERS) Database. Therapeutic innovation & regulatory science 2025. link 52 Wen MT, Luo D, Li JC, Lu BW, Ling PX, Liu F et al.. Comparing musculoskeletal and connective tissue disorder risks of teriparatide and abaloparatide in osteoporosis: an analysis based on FDA adverse event reporting system (FAERS). Expert opinion on drug safety 2025. link 53 Macrae F, Clark EM, Walsh K, Bailey SJ, Roy M, Hardcastle S et al.. Cardiovascular risk assessment for osteoporosis patients considering Romosozumab. Bone 2025. link 54 Lin YC, Chiang PH, Huang JY, Wu WS. Osteoporotic fracture risks of thiazides and dihydropyridines in angiotensin modulator users. Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 2025. link 55 de Bruin IJA, Wyers CE, Vranken L, Schousboe JT, van der Velde RY, Janzing HMJ et al.. Systematic evaluation of abdominal aortic calcification in patients with a recent clinical fracture visiting the Fracture Liaison Service. Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 2025. link 56 Zhao AY, Oguejiofor A, Harris AB, Wang K, Gu A, Melvin JS et al.. Hormone Replacement Therapy in Postmenopausal Women Undergoing Total Hip Arthroplasty is Associated With Reduced 10-Year Periprosthetic Femoral Fracture Rate. The Journal of arthroplasty 2025. link 57 Leal-Vega L, Coco-Martín MB, Martín-Gutiérrez A, Blázquez-Cabrera JA, Arranz-García F, Navarro A et al.. Effect of comorbidities and multimorbidity on bone mineral density in patients with osteoporosis. Archives of osteoporosis 2025. link 58 Analay P, Kara M, Fırat HG, Çolak AF, Erdoğan K, Aksakal MF et al.. The Relationship Between Antihypertensive Drugs and Osteoporosis in Postmenopausal Women: The ADiOS Study. Journal of clinical densitometry : the official journal of the International Society for Clinical Densitometry 2025. link 59 Liu S, Tan Y, Huang W, Luo H, Pan B, Wu S. Cardiovascular safety of zoledronic acid in the treatment of primary osteoporosis: A meta-analysis and systematic review. Seminars in arthritis and rheumatism 2024. link 60 Jeka S, Dokoupilová E, Kivitz A, Żuchowski P, Vogg B, Krivtsova N et al.. Equivalence trial of proposed denosumab biosimilar GP2411 and reference denosumab in postmenopausal osteoporosis: the ROSALIA study. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 2024. link 61 Kobayashi T, Morimoto T, Ito K, Mawatari M, Shimazaki T. Denosumab vs. bisphosphonates in primary osteoporosis: a meta-analysis of comparative safety in randomized controlled trials. Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 2024. link 62 Paccou J, Yavropoulou MP, Naciu AM, Chandran M, Messina OD, Rolvien T et al.. Prevention and treatment of glucocorticoid-induced osteoporosis in adults: recommendations from the European Calcified Tissue Society. European journal of endocrinology 2024. link 63 Wang F, Wei W, Liu PJ. Effects of probiotic supplementation on bone health in postmenopausal women: a systematic review and meta-analysis. Frontiers in endocrinology 2024. link 64 Anagnostis P, Lampropoulou-Adamidou K, Bosdou JK, Trovas G, Galanis P, Chronopoulos E et al.. Comparative Effectiveness of Therapeutic Interventions in Pregnancy and Lactation-Associated Osteoporosis: A Systematic Review and Meta-analysis. The Journal of clinical endocrinology and metabolism 2024. link 65 Hsu HH, Chiu CY, Chen WC, Yang YR, Wang RY. Effects of exercise on bone density and physical performance in postmenopausal women: A systematic review and meta-analysis. PM & R : the journal of injury, function, and rehabilitation 2024. link 66 Li M, Ge Z, Zhang B, Sun L, Wang Z, Zou T et al.. Efficacy and safety of teriparatide vs. bisphosphonates and denosumab vs. bisphosphonates in osteoporosis not previously treated with bisphosphonates: a systematic review and meta-analysis of randomized controlled trials. Archives of osteoporosis 2024. link 67 Ji W, Pan B, Chen X, Lao Z, Yang W, Qian Y. Mendelian randomization studies of risk and protective factors for osteoporosis: a systematic review and meta-analysis. Frontiers in endocrinology 2024. link 68 Chen Q, Shen P, Zhang B, Chen Y, Zhen C. The role of neridronate in the management of osteoporosis: A meta-analysis. Advances in clinical and experimental medicine : official organ Wroclaw Medical University 2024. link 69 Zhang Y, Chen H. Effect of Tai Chi exercise on bone health and fall prevention in postmenopausal women: a meta-analysis. Journal of orthopaedic surgery and research 2024. link 70 Ramchand SK, Tsai JN, Lee H, Sassana-Khadka G, Jordan M, Ryan S et al.. The comparison of alendronate and raloxifene after denosumab (CARD) study: A comparative efficacy trial. Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 2024. link 71 Lane J, Langdahl B, Stone M, Kurth A, Oates M, Timoshanko J et al.. Romosozumab in patients who experienced an on-study fracture: post hoc analyses of the FRAME and ARCH phase 3 trials. Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 2024. link 72 Sheth NP, Smith JR, Winzenrieth R, Humbert L, Wang Y, Boxberger JI et al.. Effects of Abaloparatide on Bone Mineral Density in Proximal Femoral Regions Corresponding to Arthroplasty Gruen Zones: A Study of Postmenopausal Women with Osteoporosis. The Journal of bone and joint surgery. American volume 2024. link 73 Pasa C, Pamungkasari EP, Doewes M, Purwanto B, Hartono H, Cilmiaty R et al.. Effect of walking and bone joint exercise on enhancing bone remodeling in menopausal women: A randomized controlled trial. Narra J 2024. link 74 Reginster JY, Czerwinski E, Wilk K, Borowy P, Strzelecka A, Budlewski T et al.. Efficacy and safety of candidate biosimilar CT-P41 versus reference denosumab: a double-blind, randomized, active-controlled, Phase 3 trial in postmenopausal women with osteoporosis. Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 2024. link 75 Bose S, Sharan K. Effect of probiotics on postmenopausal bone health: a preclinical meta-analysis. The British journal of nutrition 2024. link 76 Brunetto O, Cassinelli HR, Espada G, Viterbo GL, Meiorin SM, Ahumada MF et al.. Guidelines for the prevention and treatment of glucocorticoid-induced osteoporosis in pediatrics. Archivos argentinos de pediatria 2024. link 77 Pal R, Banerjee M, Prasad TN, Walia R, Bhadada T, Singh J et al.. Fracture risk and bone health in adrenal adenomas with mild autonomous cortisol secretion/subclinical hypercortisolism: a systematic review, meta-analysis and meta-regression. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 2024. link 78 Rizzoli R, Chevalley T. Bone health: biology and nutrition. Current opinion in clinical nutrition and metabolic care 2024. link 79 Porcu G, Biffi A, Ronco R, Adami G, Alvaro R, Bogini R et al.. Refracture following vertebral fragility fracture when bone fragility is not recognized: summarizing findings from comparator arms of randomized clinical trials. Journal of endocrinological investigation 2024. link 80 Zaman MU, Fatima N. Dual Energy X-ray Absorptiometry (DXA) in the Management of Osteoporosis. Journal of the College of Physicians and Surgeons--Pakistan : JCPSP 2024. link 81 Leslie WD, Binkley N, Hans D. Effects of Lumbar Spine Vertebral Fractures on Trabecular Bone Score (TBS): The Manitoba BMD Registry. Journal of clinical densitometry : the official journal of the International Society for Clinical Densitometry 2024. link 82 Somay E. Osteonecrosis of the jaws in patients under osteoporosis treatment: a nine-year experience report. Archives of endocrinology and metabolism 2024. link 83 Lin YH, Teng MMH. Effect of excluding fractured or abnormal vertebrae on the trabecular bone score measurement. Archives of osteoporosis 2024. link 84 Kim SM, Sultana F, Korkmaz F, Rojekar S, Pallapati A, Ryu V et al.. Neuroendocrinology of bone. Pituitary 2024. link 85 Wáng YXJ, Guglielmi G, Guermazi A, Kwok TCY, Griffith JF. Much lower prevalence and severity of spine degenerative changes among older Chinese women than among older Caucasian women and its implication for the interpretation of lumbar spine BMD T-score for Chinese women. Skeletal radiology 2024. link 86 Zou D, He X, Shang Z, Jin D, Li W. Osteoporosis screening using QCT-based cutoff value of Hounsfield units in patients with degenerative lumbar diseases. European spine journal : official publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research Society 2024. link 87 Xi Z, Xie Y, Sun S, Wang N, Chen S, Kang X et al.. Stepwise reduction of bony density in patients induces a higher risk of annular tears by deteriorating the local biomechanical environment. The spine journal : official journal of the North American Spine Society 2024. link 88 Ye C, Leslie WD, Bouxsein ML, Dufour AB, Guermazi A, Habtemariam D et al.. Association of vertebral fractures with worsening degenerative changes of the spine: a longitudinal study. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 2024. link 89 Li W, Niu Y, Qiu Z, Zhou S, Zhong W, Xiong Z et al.. New evidence on the controversy over the correlation between vertebral osteoporosis and intervertebral disc degeneration: a systematic review of relevant animal studies. European spine journal : official publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research Society 2024. link 90 Shi T, Shou F, Xia Q, Zhang T, Teng D, Jing W et al.. Effects of anti-osteoporosis treatment in elderly patients with osteoporosis and lumbar discectomy and fusion. Journal of back and musculoskeletal rehabilitation 2024. link 91 Xi Z, Xie Y, Sun S, Wang N, Chen S, Wang G et al.. IVD fibrosis and disc collapse comprehensively aggravate vertebral body disuse osteoporosis and zygapophyseal joint osteoarthritis by posteriorly shifting the load transmission pattern. Computers in biology and medicine 2024. link 92 Xue C, Lu X, Sun G, Wang N, He G, Xu W et al.. Opportunistic prediction of osteoporosis in patients with degenerative lumbar diseases: a simplified T12 vertebral bone quality approach. Journal of orthopaedic surgery and research 2024. link 93 Liu G, Zhang H, Chen M, Chen W. Causal relationship between intervertebral disc degeneration and osteoporosis: a bidirectional two-sample Mendelian randomization study. Frontiers in endocrinology 2024. link 94 Iwata S, Hashizume H, Yoshimura N, Oka H, Iwahashi H, Ishimoto Y et al.. Osteoporosis, spinal degenerative disorders, and their association with low back pain, activities of daily living, and physical performance in a general population. Scientific reports 2024. link 95 Kara M, Kara Ö, Durmuş ME, Analay P, Şener FE, Çıtır BN et al.. The Relationship Among Probable SARCopenia, Osteoporosis and SuprasPinatus Tendon Tears in Postmenopausal Women: The SARCOSP Study. Calcified tissue international 2024. link 96 Zhao Y, Shang D, Zhang Y, Geng Z, Li D, Song Q et al.. The effectiveness of intravenous zoledronic acid in elderly patients with osteoporosis after rotator cuff repair: a retrospective study. Scientific reports 2024. link 97 Rapp K, Schöne D, Roigk P, Becker C, Jaensch A, Rothenbacher D et al.. Association of orthogeriatric co-management with prescription frequencies of anti-osteoporotic drugs in patients with fragility fractures: An observational study with health insurance data. Injury 2024. link 98 García-Maldonado E, Gallego-Narbón A, Zapatera B, Alcorta A, Martínez-Suárez M, Vaquero MP. Bone Remodelling, Vitamin D Status, and Lifestyle Factors in Spanish Vegans, Lacto-Ovo Vegetarians, and Omnivores. Nutrients 2024. link 99 Merlijn T, Swart KMA, Niemeijer C, van der Horst HE, Netelenbos CJ, Elders PJM. The yield of routine laboratory examination in osteoporosis evaluation in primary care. Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 2024. link 100 Skalny AV, Aschner M, Tsatsakis A, Rocha JBT, Santamaria A, Spandidos DA et al.. Role of vitamins beyond vitamin D. International journal of molecular medicine 2024. link

Original source

[1]
A systematic review and meta-analysis of sequential treatment strategies for osteoporosis. — Nayak S, Greenspan SL Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA (2026)
[2]
Mining the FAERS database reveals new safety signals for 120 mg denosumab in oncology practice. — Lu S, Wang D, Xiong C, Liang J, Li Y, Liang C et al. PloS one (2026)
[3]
Ventricular and supraventricular ectopic beats burden is correlated with bone mineral density and osteoporotic fracture risk in postmenopausal women. — Kawińska A, Sewerynek E, Krekora J, Kurpesa M, Kasprzak JD, Wranicz JK Kardiologia polska (2026)
[4]
Malignant transformation in patients with monoclonal gammopathy of undetermined significance treated with teriparatide for osteoporosis: a bicenter retrospective study and analysis of the French national pharmacovigilance database. — Cassez R, Cortet B, Bouvard B, Theis D, Potey C, Manier S et al. Archives of osteoporosis (2026)
[5]
Cardiovascular Risk of Romosozumab vs. Teriparatide: A Cohort Study Using Japan's National Claims Database. — Maruyama H, Iwasa E, Watanabe S, Hasegawa T, Kajiyama K, Tanaka T Clinical pharmacology and therapeutics (2026)
[6]
Bone mineral density as a mediator in the association of abdominal aortic calcification with mortality among the general population aged over 50. — Yuan Y, Li Y, Yu X, Fan H, Peng H, Yang Y Nutrition, metabolism, and cardiovascular diseases : NMCD (2026)
[7]
Comprehensive bioinformatics analysis and experimental validation reveal the role of circadian rhythm-related genes in the crosstalk between osteoporosis and atherosclerosis. — Liu T, Fan J, Fang J, Qu Z, He Y, Yang K et al. Mammalian genome : official journal of the International Mammalian Genome Society (2026)
[8]
Denosumab and Cardiovascular Risk in Dialysis Patients With Osteoporosis: A Retrospective Cohort Study. — Lam JR, Otabor E, Alomari L, Barnett M, Lo KB, Tan IJ Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases (2026)
[9]
Considerations regarding the use of romosozumab in a patient at high risk for cardiovascular disease. — McClung MR Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research (2026)
[10]
Macrophagic Sclerostin Loop2-ApoER2 Interaction Required by Sclerostin for Cardiovascular Protective Action. — Wang L, Tao X, Zhang N, Yang X, Jiang H, Li X et al. Advanced science (Weinheim, Baden-Wurttemberg, Germany) (2026)
[11]
Association between low-carbohydrate-diet score and osteoporosis in hypertensive patients: a cross-sectional study. — Liu X, Ying H, Wang Q, Liao S, Xu B Annals of human biology (2026)
[12]
Clinical Practice Guideline: The Diagnosis and Treatment of Osteoporosis. — Thomasius F, Kurth A, Baum E, Drey M, Maus U, Schmidmaier R Deutsches Arzteblatt international (2025)
[13]
Updated practice guideline for dual-energy X-ray absorptiometry (DXA). — Slart RHJA, Punda M, Ali DS, Bazzocchi A, Bock O, Camacho P et al. European journal of nuclear medicine and molecular imaging (2025)
[14]
The 2024 UK clinical guideline for the prevention and treatment of osteoporosis. — Gregson CL, Armstrong DJ, Avgerinou C, Bowden J, Cooper C, Douglas L et al. Archives of osteoporosis (2025)
[15]
Fracture Prevention with Infrequent Zoledronate in Women 50 to 60 Years of Age. — Bolland MJ, Nisa Z, Mellar A, Gasteiger C, Pinel V, Mihov B et al. The New England journal of medicine (2025)
[16]
Update of the SEIOMM clinical guideline of osteoporosis: abaloparatide. — Riancho JA, Martín Millán M, Peris P, Martínez G Revista clinica espanola (2025)
[17]
Screening for Osteoporosis to Prevent Fractures: US Preventive Services Task Force Recommendation Statement. — Nicholson WK, Silverstein M, Wong JB, Chelmow D, Coker TR, Davis EM et al. JAMA (2025)
[18]
Effect of different types of exercise on bone mineral density in postmenopausal women: a systematic review and network meta-analysis. — Xiaoya L, Junpeng Z, Li X, Haoyang Z, Xueying F, Yu W Scientific reports (2025)
[19]
Assessing the Efficacy of Romosozumab in Postmenopausal Osteoporosis: An Updated Systematic Review and Meta-analysis. — Ferrer BL, Garcia MSM, Herrera SR, Dubuc CAE, Mariscal G, Mateu JB Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases (2025)
[20]
Cardiovascular Safety of Romosozumab Compared to Commonly Used Anti-osteoporosis Medications in Postmenopausal Osteoporosis: A Systematic Review and Network Meta-analysis of Randomized Controlled Trials. — Cheng SH, Chu W, Chou WH, Chu WC, Kang YN Drug safety (2025)
[21]
Association of dietary patterns with osteoporosis risk: a meta-analysis of observational studies. — Tan B, Su H, Wei L, Liang M Journal of orthopaedic surgery and research (2025)
[22]
Optimal resistance training parameters for improving bone mineral density in postmenopausal women: a systematic review and meta-analysis. — Zhao F, Su W, Sun Y, Wang J, Lu B, Yun H Journal of orthopaedic surgery and research (2025)
[23]
Effects of dietary supplements on bone turnover markers in women after menopause: a network meta-analysis. — Wei Y, Lei C, Zhong Y, Shen H PeerJ (2025)
[24]
Dental Implant Failure and Medication-Related Osteonecrosis of the Jaw Related to Dental Implants in Patients Taking Antiresorptive Therapy for Osteoporosis: A Systematic Review and Meta-Analysis. — Mirza R, El Rabbany M, Ali DS, Tetradis S, Morrison A, Ruggiero S et al. Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists (2025)
[25]
Effect of rhPTH(1-34) and alendronate on the treatment of type 2 diabetic bone disease. — Li H, Yuan L, Liu P, Liu Y, Huang D, Ding H et al. Frontiers in endocrinology (2025)
[26]
Vitamin D and calcium supplementation in women undergoing pharmacological management for postmenopausal osteoporosis: a level I of evidence systematic review. — Migliorini F, Maffulli N, Colarossi G, Filippelli A, Memminger M, Conti V European journal of medical research (2025)
[27]
Long-term adherence to anti-osteoporosis medication and determinants of adherence in the population-based screening trial ROSE. — Petersen TG, Rubin KH, Javaid MK, Hermann AP, Åkesson KE, Abrahamsen B Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA (2025)
[28]
A cost-saving analysis of pharmacologic management in osteoporotic fracture prevention among postmenopausal women. — Cassinat J, Wright V Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA (2025)
[29]
Ukrainian guideline for the prevention and treatment of glucocorticoid-induced osteoporosis. — Grygorieva NV, Kovalenko VM, Кorzh MO, Tronko MD, Golovach IY, Dedukh NV et al. Archives of osteoporosis (2025)
[30]
2024 Royal Australian College of General Practitioners and Healthy Bones Australia guideline for osteoporosis management and fracture prevention in postmenopausal women and men over 50 years of age. — Wong P, Chen W, Ewald D, Girgis C, Rawlin M, Tsingos J et al. The Medical journal of Australia (2025)
[31]
ESR Essentials: percutaneous bone consolidation-practice recommendations by the European Society of Musculoskeletal Radiology. — Le Corroller T, Arrigoni F European radiology (2025)
[32]
Guideline summary review: an evidence-based clinical guideline for the diagnosis and treatment of adults with osteoporotic vertebral compression fractures. — Cho CH, Hwang SW, Mazanec DJ, O'Toole JE, Watters WC, Annaswamy TM et al. The spine journal : official journal of the North American Spine Society (2025)
[33]
Assessing endocrinology referral rates and osteoporosis directed-care after upper extremity fragility fractures. — Hiredesai AN, Holle AM, Payne CS, Beckett NC, Howlett CP, Lai CH et al. Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA (2025)
[34]
Cardiovascular risk in patients with osteoporosis within a Rheumatology setting. Results from a Spanish survey-based multicenter study. — Casado E, Gómez-Olmedo I Reumatologia clinica (2025)
[35]
Biomechanical Effects of Oblique Lumbar Interbody Fusion on Adjacent Segment Degeneration After Surgery in Patients with Osteoporosis: A Finite Element Study. — Wang L, Ren J, Chang H, Li H, Wang Z, Liang G et al. World neurosurgery (2025)
[36]
Relationship between Preoperative Adjacent Disc Height and the Occurrence of Adjacent Vertebral Body Fractures after Balloon Kyphoplasty for Osteoporotic Fractures at the Thoracolumbar Junction. — Ishii M, Nishimura Y, Yamamoto Y, Nagashima Y, Tanei T, Hara M et al. Neurologia medico-chirurgica (2025)
[37]
Crosstalk between osteoporosis and fat-infiltrated psoas at the upper lumbar levels. — Özcan-Ekşi EE, Osama M, Ekşi MŞ European spine journal : official publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research Society (2025)
[38]
Would Roussouly classification affect the diagnostic efficiency of vertebral bone quality score for assessing osteopenia or osteoporosis in lumbar degenerative disease? — Su T, Meng T, Zhao K, Song D, Huang W, Yin H European spine journal : official publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research Society (2025)
[39]
A Random Study of Comparing the Efficacy of Antiosteoporosis Therapy at Different Time Points Combined With Oblique Lateral Interbody Fusion in the Treatment of Lumbar Degenerative Disease Patients Complicated With Osteoporosis. — Zhao H, Dong X, Bao X, Zhang X, Ren K, Qiao H et al. Clinical spine surgery (2025)
[40]
Bone cement distribution patterns influence cage subsidence after OLIF-AF-SEA in elderly patients with osteoporotic lumbar degeneration. — Hu X, Xie T, Pu X, Luo C, Peng X, Wang X et al. Journal of orthopaedic surgery and research (2025)
[41]
Low bone mineral density as a causal risk factor for cervical and thoracolumbar intervertebral disc degeneration: A Mendelian randomization analysis. — Huang L, Yang Q, Xu H, Feng J, Liu D, Jiang H Medicine (2025)
[42]
Effects of lumbar degeneration on the global and regional bone mineral density in osteoporotic patients requiring lumbar interbody fusion for degenerative lumbar diseases. — Zhao Y, Zou D, He H, Shang Z, Li W European spine journal : official publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research Society (2025)
[43]
Co-morbid mechanisms of intervertebral disc degeneration and osteoporosis: biomechanical coupling and molecular pathways synergistically driving degenerative lesions. — Ling Z, Zeng X, Luo Q, Li X, Cui L Journal of orthopaedic surgery and research (2025)
[44]
Association between osteoporosis and rotator cuff tears: evidence from causal inference and colocalization analyses. — Liu Y, Zhao R, Huang Z, Li F, Li X, Zhou K et al. Bone research (2025)
[45]
Quantitative computed tomography analysis of bone microarchitecture is associated with rotator cuff healing. — Yin H, Ding Y, Feng Z, Yan Z, Guo A Journal of orthopaedic surgery and research (2025)
[46]
Understanding the impact of multimorbidity, medications and frailty on zoledronic acid efficacy in treating osteoporosis among older adults. — Ozcan B, Ceylan S, Ozcan M, Guner M, Balcı C, Cankurtaran M et al. British journal of clinical pharmacology (2025)
[47]
Mining and analysis of adverse event signals for alendronate based on the real-world data of FDA adverse event reporting system database. — Zhao Z, Ji H, Zhang C, Wang Z, Ren S, Liu C et al. Expert opinion on drug safety (2025)
[48]
Adverse events associated with teriparatide: a real-world disproportionality analysis of the FDA adverse event reporting system (FAERS). — Dai Z, Zhang J, Tao Z, Gao R, Zhao Q Expert opinion on drug safety (2025)
[49]
Romosozumab adverse event profile: a pharmacovigilance analysis based on the FDA Adverse Event Reporting System (FAERS) from 2019 to 2023. — Liu L, Wu S, Wei L, Xia Z, Ji J, Huang D Aging clinical and experimental research (2025)
[50]
Sex differences in drug-induced osteoporosis: a pharmacovigilance study based on the FAERS database. — Liu L, Song Y, Liu X, Song B, Song M Frontiers in public health (2025)
[51]
Hypocalcemia Event Associated with Denosumab: A Real-World Study from FDA Adverse Event Reporting System (FAERS) Database. — Gao S, Zheng G, He Z, Chen L, Yan D, Lai Z et al. Therapeutic innovation & regulatory science (2025)
[52]
Comparing musculoskeletal and connective tissue disorder risks of teriparatide and abaloparatide in osteoporosis: an analysis based on FDA adverse event reporting system (FAERS). — Wen MT, Luo D, Li JC, Lu BW, Ling PX, Liu F et al. Expert opinion on drug safety (2025)
[53]
Cardiovascular risk assessment for osteoporosis patients considering Romosozumab. — Macrae F, Clark EM, Walsh K, Bailey SJ, Roy M, Hardcastle S et al. Bone (2025)
[54]
Osteoporotic fracture risks of thiazides and dihydropyridines in angiotensin modulator users. — Lin YC, Chiang PH, Huang JY, Wu WS Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA (2025)
[55]
Systematic evaluation of abdominal aortic calcification in patients with a recent clinical fracture visiting the Fracture Liaison Service. — de Bruin IJA, Wyers CE, Vranken L, Schousboe JT, van der Velde RY, Janzing HMJ et al. Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA (2025)
[56]
Hormone Replacement Therapy in Postmenopausal Women Undergoing Total Hip Arthroplasty is Associated With Reduced 10-Year Periprosthetic Femoral Fracture Rate. — Zhao AY, Oguejiofor A, Harris AB, Wang K, Gu A, Melvin JS et al. The Journal of arthroplasty (2025)
[57]
Effect of comorbidities and multimorbidity on bone mineral density in patients with osteoporosis. — Leal-Vega L, Coco-Martín MB, Martín-Gutiérrez A, Blázquez-Cabrera JA, Arranz-García F, Navarro A et al. Archives of osteoporosis (2025)
[58]
The Relationship Between Antihypertensive Drugs and Osteoporosis in Postmenopausal Women: The ADiOS Study. — Analay P, Kara M, Fırat HG, Çolak AF, Erdoğan K, Aksakal MF et al. Journal of clinical densitometry : the official journal of the International Society for Clinical Densitometry (2025)
[59]
Cardiovascular safety of zoledronic acid in the treatment of primary osteoporosis: A meta-analysis and systematic review. — Liu S, Tan Y, Huang W, Luo H, Pan B, Wu S Seminars in arthritis and rheumatism (2024)
[60]
Equivalence trial of proposed denosumab biosimilar GP2411 and reference denosumab in postmenopausal osteoporosis: the ROSALIA study. — Jeka S, Dokoupilová E, Kivitz A, Żuchowski P, Vogg B, Krivtsova N et al. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research (2024)
[61]
Denosumab vs. bisphosphonates in primary osteoporosis: a meta-analysis of comparative safety in randomized controlled trials. — Kobayashi T, Morimoto T, Ito K, Mawatari M, Shimazaki T Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA (2024)
[62]
Prevention and treatment of glucocorticoid-induced osteoporosis in adults: recommendations from the European Calcified Tissue Society. — Paccou J, Yavropoulou MP, Naciu AM, Chandran M, Messina OD, Rolvien T et al. European journal of endocrinology (2024)
[63]
Effects of probiotic supplementation on bone health in postmenopausal women: a systematic review and meta-analysis. — Wang F, Wei W, Liu PJ Frontiers in endocrinology (2024)
[64]
Comparative Effectiveness of Therapeutic Interventions in Pregnancy and Lactation-Associated Osteoporosis: A Systematic Review and Meta-analysis. — Anagnostis P, Lampropoulou-Adamidou K, Bosdou JK, Trovas G, Galanis P, Chronopoulos E et al. The Journal of clinical endocrinology and metabolism (2024)
[65]
Effects of exercise on bone density and physical performance in postmenopausal women: A systematic review and meta-analysis. — Hsu HH, Chiu CY, Chen WC, Yang YR, Wang RY PM & R : the journal of injury, function, and rehabilitation (2024)
[66]
Efficacy and safety of teriparatide vs. bisphosphonates and denosumab vs. bisphosphonates in osteoporosis not previously treated with bisphosphonates: a systematic review and meta-analysis of randomized controlled trials. — Li M, Ge Z, Zhang B, Sun L, Wang Z, Zou T et al. Archives of osteoporosis (2024)
[67]
Mendelian randomization studies of risk and protective factors for osteoporosis: a systematic review and meta-analysis. — Ji W, Pan B, Chen X, Lao Z, Yang W, Qian Y Frontiers in endocrinology (2024)
[68]
The role of neridronate in the management of osteoporosis: A meta-analysis. — Chen Q, Shen P, Zhang B, Chen Y, Zhen C Advances in clinical and experimental medicine : official organ Wroclaw Medical University (2024)
[69]
Effect of Tai Chi exercise on bone health and fall prevention in postmenopausal women: a meta-analysis. — Zhang Y, Chen H Journal of orthopaedic surgery and research (2024)
[70]
The comparison of alendronate and raloxifene after denosumab (CARD) study: A comparative efficacy trial. — Ramchand SK, Tsai JN, Lee H, Sassana-Khadka G, Jordan M, Ryan S et al. Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA (2024)
[71]
Romosozumab in patients who experienced an on-study fracture: post hoc analyses of the FRAME and ARCH phase 3 trials. — Lane J, Langdahl B, Stone M, Kurth A, Oates M, Timoshanko J et al. Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA (2024)
[72]
Effects of Abaloparatide on Bone Mineral Density in Proximal Femoral Regions Corresponding to Arthroplasty Gruen Zones: A Study of Postmenopausal Women with Osteoporosis. — Sheth NP, Smith JR, Winzenrieth R, Humbert L, Wang Y, Boxberger JI et al. The Journal of bone and joint surgery. American volume (2024)
[73]
Effect of walking and bone joint exercise on enhancing bone remodeling in menopausal women: A randomized controlled trial. — Pasa C, Pamungkasari EP, Doewes M, Purwanto B, Hartono H, Cilmiaty R et al. Narra J (2024)
[74]
Efficacy and safety of candidate biosimilar CT-P41 versus reference denosumab: a double-blind, randomized, active-controlled, Phase 3 trial in postmenopausal women with osteoporosis. — Reginster JY, Czerwinski E, Wilk K, Borowy P, Strzelecka A, Budlewski T et al. Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA (2024)
[75]
Effect of probiotics on postmenopausal bone health: a preclinical meta-analysis. — Bose S, Sharan K The British journal of nutrition (2024)
[76]
Guidelines for the prevention and treatment of glucocorticoid-induced osteoporosis in pediatrics. — Brunetto O, Cassinelli HR, Espada G, Viterbo GL, Meiorin SM, Ahumada MF et al. Archivos argentinos de pediatria (2024)
[77]
Fracture risk and bone health in adrenal adenomas with mild autonomous cortisol secretion/subclinical hypercortisolism: a systematic review, meta-analysis and meta-regression. — Pal R, Banerjee M, Prasad TN, Walia R, Bhadada T, Singh J et al. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research (2024)
[78]
Bone health: biology and nutrition. — Rizzoli R, Chevalley T Current opinion in clinical nutrition and metabolic care (2024)
[79]
Refracture following vertebral fragility fracture when bone fragility is not recognized: summarizing findings from comparator arms of randomized clinical trials. — Porcu G, Biffi A, Ronco R, Adami G, Alvaro R, Bogini R et al. Journal of endocrinological investigation (2024)
[80]
Dual Energy X-ray Absorptiometry (DXA) in the Management of Osteoporosis. — Zaman MU, Fatima N Journal of the College of Physicians and Surgeons--Pakistan : JCPSP (2024)
[81]
Effects of Lumbar Spine Vertebral Fractures on Trabecular Bone Score (TBS): The Manitoba BMD Registry. — Leslie WD, Binkley N, Hans D Journal of clinical densitometry : the official journal of the International Society for Clinical Densitometry (2024)
[82]
Osteonecrosis of the jaws in patients under osteoporosis treatment: a nine-year experience report. — Somay E Archives of endocrinology and metabolism (2024)
[83]
Effect of excluding fractured or abnormal vertebrae on the trabecular bone score measurement. — Lin YH, Teng MMH Archives of osteoporosis (2024)
[84]
Neuroendocrinology of bone. — Kim SM, Sultana F, Korkmaz F, Rojekar S, Pallapati A, Ryu V et al. Pituitary (2024)
[85]
Much lower prevalence and severity of spine degenerative changes among older Chinese women than among older Caucasian women and its implication for the interpretation of lumbar spine BMD T-score for Chinese women. — Wáng YXJ, Guglielmi G, Guermazi A, Kwok TCY, Griffith JF Skeletal radiology (2024)
[86]
Osteoporosis screening using QCT-based cutoff value of Hounsfield units in patients with degenerative lumbar diseases. — Zou D, He X, Shang Z, Jin D, Li W European spine journal : official publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research Society (2024)
[87]
Stepwise reduction of bony density in patients induces a higher risk of annular tears by deteriorating the local biomechanical environment. — Xi Z, Xie Y, Sun S, Wang N, Chen S, Kang X et al. The spine journal : official journal of the North American Spine Society (2024)
[88]
Association of vertebral fractures with worsening degenerative changes of the spine: a longitudinal study. — Ye C, Leslie WD, Bouxsein ML, Dufour AB, Guermazi A, Habtemariam D et al. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research (2024)
[89]
New evidence on the controversy over the correlation between vertebral osteoporosis and intervertebral disc degeneration: a systematic review of relevant animal studies. — Li W, Niu Y, Qiu Z, Zhou S, Zhong W, Xiong Z et al. European spine journal : official publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research Society (2024)
[90]
Effects of anti-osteoporosis treatment in elderly patients with osteoporosis and lumbar discectomy and fusion. — Shi T, Shou F, Xia Q, Zhang T, Teng D, Jing W et al. Journal of back and musculoskeletal rehabilitation (2024)
[91]
IVD fibrosis and disc collapse comprehensively aggravate vertebral body disuse osteoporosis and zygapophyseal joint osteoarthritis by posteriorly shifting the load transmission pattern. — Xi Z, Xie Y, Sun S, Wang N, Chen S, Wang G et al. Computers in biology and medicine (2024)
[92]
Opportunistic prediction of osteoporosis in patients with degenerative lumbar diseases: a simplified T12 vertebral bone quality approach. — Xue C, Lu X, Sun G, Wang N, He G, Xu W et al. Journal of orthopaedic surgery and research (2024)
[93]
Causal relationship between intervertebral disc degeneration and osteoporosis: a bidirectional two-sample Mendelian randomization study. — Liu G, Zhang H, Chen M, Chen W Frontiers in endocrinology (2024)
[94]
Osteoporosis, spinal degenerative disorders, and their association with low back pain, activities of daily living, and physical performance in a general population. — Iwata S, Hashizume H, Yoshimura N, Oka H, Iwahashi H, Ishimoto Y et al. Scientific reports (2024)
[95]
The Relationship Among Probable SARCopenia, Osteoporosis and SuprasPinatus Tendon Tears in Postmenopausal Women: The SARCOSP Study. — Kara M, Kara Ö, Durmuş ME, Analay P, Şener FE, Çıtır BN et al. Calcified tissue international (2024)
[96]
The effectiveness of intravenous zoledronic acid in elderly patients with osteoporosis after rotator cuff repair: a retrospective study. — Zhao Y, Shang D, Zhang Y, Geng Z, Li D, Song Q et al. Scientific reports (2024)
[97]
Association of orthogeriatric co-management with prescription frequencies of anti-osteoporotic drugs in patients with fragility fractures: An observational study with health insurance data. — Rapp K, Schöne D, Roigk P, Becker C, Jaensch A, Rothenbacher D et al. Injury (2024)
[98]
Bone Remodelling, Vitamin D Status, and Lifestyle Factors in Spanish Vegans, Lacto-Ovo Vegetarians, and Omnivores. — García-Maldonado E, Gallego-Narbón A, Zapatera B, Alcorta A, Martínez-Suárez M, Vaquero MP Nutrients (2024)
[99]
The yield of routine laboratory examination in osteoporosis evaluation in primary care. — Merlijn T, Swart KMA, Niemeijer C, van der Horst HE, Netelenbos CJ, Elders PJM Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA (2024)
[100]
Role of vitamins beyond vitamin D — Skalny AV, Aschner M, Tsatsakis A, Rocha JBT, Santamaria A, Spandidos DA et al. International journal of molecular medicine (2024)

Share:Twitter Reddit LinkedIn